计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
SB505124是一种选择性TGFβR抑制剂,作用于ALK4和ALK5,无细胞试验中IC50分别为129 nM和47 nM,也抑制ALK7,但不抑制ALK1,2,3或6。An inhibitor of Activin receptor-like kinase 5
Information
SB505124 is a selective inhibitor ofTGFβRforALK4,ALK5withIC50of 129 nM and 47 nM in cell-free assays, respectively, also inhibitsALK7, but does not inhibit ALK1, 2, 3, or 6.
In vitro
SB505124 is identified as a reversible ATP competitive and selective ALK inhibitor of ALK4 and ALK5. SB505124 shows no toxicity to renal epithelial A498 cells at concentrations up to 100 μM for 48 hours, and blocks TGF-β–induced apoptosis of FaO cells and NRP 154 cells in a concentration-dependent manner. In human umbilical vein endothelial cells (HUVEC), SB505124 (500 nM) blocks the changes of TGF-β1 on F-actin assembly and prevents ROS production induced by TGF-β. By inhibiting TGF-beta1 signaling, SB505124 leads to decreased deferoxamine (DFO)-induced neurogenesis. A recent study shows that SB505124 suppresses the migration and invasion of breast cancer MCF-7-M5 cells.
In vivo
In a rabbit GFS model, SB505124 decreased the intraocular pressure (IOP) levels and reduces subconjunctival cell infiltration and scarring at the surgical site in the GFS. In tacrolimus (TAC)-treated mice and FK12EC KO mice, SB505124 prevents the activation of endothelial TGF-β receptors and induction of renal arteriolar hyalinosis.
Cell Data
cell lines:
Concentrations:0-10 μM
Incubation Time:48 hours
Powder Purity:≥98%